Azathioprine Rheumatology Shared Care Request Form National Format(70 KB)
Date added: 26th Oct 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| BECLOMETASONE Inhaler - CFC free (UPDATED) | Green | Asthma |
QVAR® brand recommended for adults. Soprobec® brand recommended only for children. Clenil Modulite® inhalers are being discontinued. Patients prescribed Clenil Modulite® 50 microgram or 100 microgram inhalers should be switched to the equivalent strength of Soprobec®, in line with the local SBAR.
Soprobec® provides a like-for-like dose of beclometasone dipropionate; however, it does not include a dose counter.
|
| EPOETIN ZETA (Retacrit®) (NEW) | Red | Anaemia |
Preferred Formulary Brand |
| FOSCARNET INTRAVITREAL (NEW) | Red | Specialist Ophthalmology use for viral retinitis |
Intravitreal injection Requires micro code |
| GANCICLOVIR INTRAVITREAL (NEW) | Red | Specialist Ophthalmology use for viral retinitis |
Intravitreal injection Requires micro code |
| LIOTHYRONINE (NEW) | Yellow | Hypothyroidism |
Monitoring will be undertaken by secondary care and patients remain open to secondary care. NICE NG145: Overview | Thyroid disease: assessment and management | Guidance | NICE NHS England » Liothyronine – advice for prescribers NHS England » Items which should not routinely be prescribed in primary care: policy guidance |
| MICONAZOLE ORAL GEL (Daktarin®) (NEW) | Green | Oral candidiasis in adults and children aged 4 months and over and Adults |
First-line option for patients aged >4 months and Adults Nystatin should be used for oral candidiasis in infants under 4 months of age, as licensed.
|
| NYSTATIN 100,000 UNIT/ML ORAL SUSPENSION (NEW) | Green | Oral candidiasis in infants aged under 4 months |
Second-line choice for patients aged >4 months and Adults |
| TICAGRELOR (NEW) | Red | For ischaemic stroke or TIA in patients known or suspected of being intermediate or poor CYP2C19 metabolisers |
Alternative to clopidogrel for secondary prevention in patients confirmed or suspected to be intermediate or poor CYP2C19 metabolisers. |
Other Updates on this Website
Recent documents from LLR APC and TAS
Penicillamine Shared Care Request Form National Format(70 KB)
Date added: 13th Oct 2026
LLR APC Meeting Minutes September 2026(447 KB) - LMSG/LLR APC minutes
Date added: 12th Oct 2026
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more